Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Call Transcript
Operator: Operator Ladies and gentlemen, welcome to the Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Profile Business Update.
Mirum Pharmaceuticals Inc. (MIRM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 2,032,335 | $48,816,687 | 1.08% | |
| 2. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,795,733 | $43,133,507 | 1.02% | |
| 3. | Citadel Investment Group Ken Griffin | 1,369,345 | $32,891,667 | -3% | 0% |
| 4. | Tang Capital Management Kevin C. Tang | 1,170,000 | $28,103,400 | +5% | 4.18% |
| 5. | Polar Capital Brian Ashford-Russell And Tim Woolley | 929,907 | $22,336,366 | +9% | 0.16% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.90 | 750 | Officer | 18,561 | 2021-11-26 | Filing | |
| $14.40 | 700 | Officer | 17,811 | 2021-11-24 | Filing | |
| $14.40 | 7,000 | Officer, Director | 28,027 | 2021-11-24 | Filing | |
| $18.65 | 1,592 | Officer | 7,871 | 2020-12-23 | Filing | |
| $18.65 | 1,562 | Officer | 7,841 | 2020-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $28.00 | 14,608 | Director | 0 | 2023-05-03 | Filing | |
| $19.69 | 93,770 | Director | 1,621,118 | 2022-11-15 | Filing | |
| $19.60 | 32,109 | Director | 1,714,888 | 2022-11-14 | Filing | |
| $19.99 | 174,121 | Director | 1,746,997 | 2022-11-11 | Filing | |
| $24.47 | 6,243 | Large Shareholder, Other | 1,540,190 | 2022-06-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 4,186,243 | $100,553,557 | 6.95% | |
| 2. | 3,860,107 | $92,719,770 | 6.71% | |
| 3. | 2,059,201 | $49,462,008 | 0.9% | |
| 4. | 1,709,826 | $41,070,020 | 0% | |
| 5. | 1,684,193 | $40,454,316 | 2.66% |
News See All
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. Thank you for attending the Mirum Pharmaceuticals Fourth Quarter and Year-End 2022 Financial Results and Business Update.
Hedge Funds Were Right About These 10 Small-Cap Stocks
In this article, we will discuss how hedge funds were right about these 10 small-cap stocks.
5 Best Healthcare Stocks Under $20 According to Michael Castor's Sio Capital
In this article, we discuss the 5 best healthcare stocks under $20 according to Michael Castor's Sio Capital.
Is MIRM A Good Stock To Buy Now?
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
Hedge Funds Are Nibbling On Mirum Pharmaceuticals, Inc. (MIRM)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first.
Is Mirum Pharmaceuticals, Inc. (MIRM) A Good Stock To Buy?
Is Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research.
Billionaire Hedge Funds
